|

Tirzepatide Clinical Trials

36 actively recruiting trials across 19 locations

▲ +1 trial since May 2026

Also known as: GIP/GLP-1RA, LY3298176, LY3298176 (development code name), Mounjaro, Mounjaro (brand name in certain regions) +6 more

Pipeline

Early 1: 3Phase 1: 2Phase 2: 10Phase 3: 4Phase 4: 12Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • Eli Lilly and Company4
  • The University of Texas Health Science Center at San Antonio2
  • University of Miami1
  • University of Melbourne1
  • University of Hawaii1

Indications

Other16 trials

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar
Phase 2/3
A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus
Phase 1/2
A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
Phase 4
A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
Phase 4
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults
N/A
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Combination of Biologic and Anti-obesity Therapies in Psoriatic Arthritis
N/A
Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes
Phase 4
Efficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
Phase 2
Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
Phase 3
GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes
Phase 3
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
Phase 1
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
Phase 4
The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
Phase 4
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
Phase 4
Tirzepatide Use in People With Obesity and Type 1 Diabetes
Phase 4

San Antonio, Texas2 trials

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

University Health System Texas Diabetic Institute

Phase 3
Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults

University of Texas Health Science Center at San Antonio

Phase 2

Tuscaloosa, Alabama1 trial

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

MFA Clinical Research

Phase 3

Avondale, Arizona1 trial

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale

Phase 4

Duarte, California1 trial

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

City of Hope Medical Center

Phase 2

Palo Alto, California1 trial

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

Stanford University

Phase 4

Torrance, California1 trial

Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT

Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute)

Phase 4

Jacksonville, Florida1 trial

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Gateway Community Services

Phase 2

Miami, Florida1 trial

Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients

University of Miami

Phase 4

Honolulu, Hawaii1 trial

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

John A Burns School of Medicine

Phase 2

Baton Rouge, Louisiana1 trial

GLP-1R Actions on Muscle and the Skeleton

Pennington Biomedical Research Center

Phase 4

Bethesda, Maryland1 trial

Tirzepatide in MetALD

National Institutes of Health Clinical Center

Phase 2

Boston, Massachusetts1 trial

Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors

Massachusetts General Hospital Cancer Center

Phase 1

Basking Ridge, New Jersey1 trial

A Study of a Weight Loss Intervention in People With Endometrial Cancer

Memorial Sloan Kettering Basking Ridge

Early 1

Elizabeth, New Jersey1 trial

Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

Trinitas Comprehensive Cancer Center

Phase 2

Chapel Hill, North Carolina1 trial

Tirzepatide in Obesity-Driven Endometrial Cancer

Lineberger Comprehensive Cancer Center

Early 1

Cleveland, Ohio1 trial

TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

Cleveland Clinic

Phase 2

Memphis, Tennessee1 trial

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

St. Jude Children's Research Hospital

Phase 2

Dallas, Texas1 trial

Tirzepatide Weight Loss for MRD+ Early Breast Cancer

Baylor University Medical Center, Baylor Charles A Sammons Cancer Center

Phase 2

Houston, Texas1 trial

Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study

The University of Texas M. D. Anderson Cancer Center

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.